Torrent Pharma Q4 Results: Profit rises 11% on-year; final dividend of ₹6 proposed

Torrent Pharmaceuticals Ltd posted a healthy performance for the March quarter, reporting a net profit of ₹498 crore, up 10.9% year-on-year from ₹449 crore in Q4FY24.

Revenue rose 7.8% to ₹2,959 crore, compared to ₹2,745 crore in the same period last year, led by growth across key geographies and therapeutic segments.

EBITDA for the quarter stood at ₹964 crore, up 9.2% from ₹883 crore, with operating margins stable at 32.6% versus 32.2% a year ago, reflecting continued cost discipline and operational efficiency.

The board has recommended a final dividend of ₹6 per equity share (120%) for the financial year ended March 2025. This is in addition to the interim dividend of ₹26 per share declared earlier, bringing the total dividend for FY25 to ₹32 per share.

Also read: J Kumar Infraprojects Q4 Results: Profit, revenue up over 14% YoY; ₹4 dividend proposed

In a key update, the board also proposed enabling resolutions to raise up to ₹5,000 crore through qualified institutional placement or other instruments, subject to shareholder approval.

Additionally, Aman Mehta, currently Whole-time Director, has been recommended for appointment as Managing Director and Whole-time Key Managerial Personnel for a five-year term starting 1 August 2025. The company affirmed that he is not debarred by any regulatory authority.

Shares of Torrent Pharma ended 1.77% lower at ₹3,244.50 on the BSE on Friday.